Asset profile
IDE397
Small molecule
Evidence outlook · lead readout
NCT05975073 · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05975073: The study is a nonrandomized, open-label, single-arm dose-exploration and dose-expansion trial without a placebo or active comparator. Its Part 2 primary outcome is objective tumor response by RECIST 1.1, but no results are posted, so whether the primary endpoint was met cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.